中成药抑制成纤维细胞胶原沉积的作用研究

Study of the effect of marketed Chinese patent medicine on inhibiting collagen deposition in fibroblasts models

关键词:  中成药  成纤维细胞  胶原沉积  新型冠状病毒肺炎

Key words:  Chinese patent medicine  fibroblasts  collagen deposition  COVID-19

摘要:

[目的] 病毒侵染呼吸系统，造成肺损伤后可引发肺纤维化。这一过程通常与肺部成纤维细胞募集、胶原沉积，细胞外基质重塑等病理过程相关，临床缺乏有效治疗药物。实验旨在寻求能有效抑制胶原沉积的中成药。[方法] 通过天狼星红法，就人源肺成纤维细胞和鼠源胚胎成纤维细胞的两种胶原沉积模型，对已上市的多种中成药进行了筛选。[结果] 发现多种中成药提取物对鼠源胚胎成纤维细胞、人源肺成纤维化细胞的胶原沉积均有抑制作用。[结论] 提示这些中成药有较好的临床应用前景，为后期新型冠状病毒肺炎康复治疗提供用药选择依据。

Abstract:

[Objective] The respiratory system infected by virus normally causes lung injury,subsequently followed by pulmonary fibrosis. This process is related to several pathological processes,such as recruitment of lung fibroblasts,collagen deposition and extracellular matrix remodeling. Currently,there is no effective therapeutic drugs in the clinic. This experiment was aim to get the marketed Chinese patent medicine with the effect of collagen deposition inhibiting.[Methods] In this paper,we screened marketed Chinese patent medicines by Sirius Red staining method using collagen deposition models of human-derived lung fibroblasts and murine-derived fibroblasts.[Results] A few marketed medicines with significant inhibition in collagen deposition both in embryonic fibroblast of mice and human fibroblasts models were screened out.[Conclusion] The results suggest that these marketed Chinese patent medicines are expected to have more promising clinical applications,and provide the basis for drug selection for the later COVID-19 rehabilitation treatment.